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Background: Many studies have been carried out to test the hypothesis that the NQO1 C609T polymorphism
might be associated with the risk of esophageal cancer. However, the results are poorly consistent, partly due to
genetic or other sources of heterogeneity. To investigate the association between this polymorphism and the risk
of esophageal cancer, a meta-analysis was performed.
Methods: We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of association. The
frequency of the putative risk allele in the controls was estimated by the inverse-variance method. Cochran’s Q
statistic and the inconsistency index (I2) were used to check heterogeneity. Egger’s test and an inverted funnel plot
were used to assess the publication bias.
Results: Our study included eight published case-control studies about the NQO1 C609T polymorphism and
esophageal cancer, including a total of 1,217 esophageal cancer patients and 1,560 controls. Overall, a
significant association was found between the NQO1 C609T variant and esophageal cancer under a recessive
model (OR = 1.647; 95% CI = 1.233-2.200). Regarding histological type, more significant evidence was found for
esophageal squamous cell carcinoma (ESCC) (OR = 2.03; 95% CI = 1.29-3.19) than esophageal adenocarcinoma
(EAC) (OR = 1.61; 95% CI = 1.01-2.56) under a recessive model.
Conclusions: The meta-analysis suggests that the NQO1 C609T polymorphism considerably increases the risk of
esophageal cancer.Background
Esophageal cancer is a malignancy of the esophagus, the
muscular tube through which food passes from the
throat to the stomach. Esophageal tumors usually lead
to dysphagia, pain and other symptoms, and are diag-
nosed by biopsy. Generally, esophageal cancer has two
subtypes, squamous cell cancer (ESCC) and adenocar-
cinoma (EAC). Squamous cell cancer arises from the
cells that line the upper part of the esophagus. Adeno-
carcinoma arises from glandular cells that are present at
the junction of the esophagus and the stomach [1].
NAD(P)H quinone oxidoreductase 1 (NQO1) is a
member of the NAD(P)H dehydrogenase (quinone)
family and encodes a cytoplasmic 2-electron reductase,
which is a cytosolic flavoenzyme that protects cells* Correspondence: chen535@126.com
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reproduction in any medium, provided the orfrom oxidative damage [2]. NQO1 catalyzes the reductive
activation of quinoid chemotherapeutic agents and envir-
onmental carcinogens such as heterocyclic amines, nitrosa-
mines and cigarette smoke condensates [3]. The NQO1 T
allele has only 2 to 4% enzymatic activity in comparison to
its wild type form. Cells homozygous for the polymorphic
NQO1 allele (T/T) express NQO1 mRNA, but not the
protein because the mutant NQO1 protein is rapidly de-
graded by the proteasomal system [4]. However, the activ-
ity of the NQO1 enzyme may be influenced by a major
polymorphism involving a single C to T substitution at nu-
cleotide 609 of exon 6 in the NQO1 cDNA that causes a
Pro187Ser amino acid change [5].
Some studies have shown that this polymorphism in
the NQO1 gene affects the translation of the NQO1
protein. Compared to the homozygous wild type (C/C),
expression of the NQO1 protein encoded by the hetero-
zygous phenotype (C/T) is decreased approximately
three-fold. In addition, the homozygous mutant (T/T)
phenotype causes a complete lack of enzyme activityLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ciated with the risk of various cancers such as renal [8],
lung [9,10], esophageal [11-13], colorectal [14], and head
and neck [15]. However, the results of some studies on
the effect of the NQO1 C609T polymorphism on
esophageal cancer are debatable. Meta-analyses are usu-
ally useful when many studies point more or less in the
same direction, but a single study does not have suffi-
cient power to show a significant result. Therefore, a
meta-analysis of these studies was undertaken to investi-
gate the association of the NQO1 C609T polymorphism
with susceptibility to esophageal cancer.
Methods
Search strategy and data extraction
All original studies published in English on the NQO1
C609T polymorphism and esophageal cancer were con-
sidered in our meta-analysis. HuGENet, Embase and
PubMed were searched up to August 8 2011, using the
following terms: (“esophageal cancer” or “esophagus” or
“ESCC” or “EAC” or “oesophagus”) and (“polymorph-
ism” or “SNP” or “allele” or “variant”) and (“NQO1” or
“NAD(P)H: quinine oxidoreductase 1” or “NAD(P)H de-
hydrogenase, quinone 1” or “DHQU”).
Included studies had to fit the following criteria:
(1) sufficient data regarding allele frequency; (2) an associ-
ation analysis between the NQO1 C609T polymorphism
and esophageal cancer risk; and (3) independent case-
control studies.
Data extraction
The following information was extracted by three inves-
tigators (Y-L H, W-W H and Y-H Z) from each study:
the first author, year of publication, country, race, sam-
ple size, outcome, characteristics of controls, case and
control diagnostic criteria, genotyping method, allele fre-
quencies, genotype distribution in cases and controls,
pathology status of esophageal cancer and the esopha-
geal cancer risk factors. Results were compared and dif-
ferent opinions were resolved by a discussion.
Statistical analysis
Hardy-Weinberg equilibrium (HWE; P ≥ 1e-03) and chi-
square test methods were used to test the distribution
of genotypes in the control group of each study. The
frequency of the putative risk allele in the controls was
estimated by the inverse-variance method [16-18].
Cochran’s Q statistic and the inconsistency index (I2)
were used to check heterogeneity [19]; if P > 0.10 and
I2 < 25%, heterogeneity did not exist among the studies
[20]. If there was no heterogeneity, logistic regression
with fixed effects was used to evaluate the overall gene
effect; otherwise, the random-effects model was used.
To determine the overall gene effect, the model thatincluded the gene was compared with the model that did
not. If the overall gene effect was statistically significant,
further comparisons of OR1 (AA vs. aa), OR2 (Aa vs. aa)
and OR3 (AA vs. Aa) were explored with A as the risk al-
lele. We selected the genetic models according to the fol-
lowing criteria [20]:
If OR1 =OR2 ≠ 1 and OR3 = 1, the dominant model
was selected.
If OR1 =OR3 ≠ 1 and OR2 = 1, the recessive model was
accepted.
If OR2 = 1/OR3 ≠ 1 and OR1 = 1, the overdominant
model was taken.
If OR1 > OR2 > 1 and OR1 > OR3 > 1(or OR1 < OR2 < 1
and OR1 < OR3 < 1), the codominant model was
adopted. Finally, the results were pooled again under
the appropriate genetic model.
Egger’s test and an inverted funnel plot was used to as-
sess publication bias [21]. HWE was checked in the con-
trol group of the eligible studies by the chi-square test
(p ≤ 0.001). Sensitivity analysis was performed including
studies that deviated from HWE. Statistical tests were
performed using the STATA software, version 11.1 (Stata
Corporation, USA). All P values were two-sided.
Results
Study inclusion and characteristics
Ten relevant studies describing the association between
NQO1 C609T and esophageal cancer were identified. How-
ever, after reading the full text, we excluded two of these
ten studies due to overlapping [22,23]. Finally, eight studies
met the inclusion criteria and were included [24-31].
Among these, five were on Caucasians [24,26-29] and three
on Asians [25,30,31]. All the included studies were case-
controlled, comprising 1,217 cases and 1,560 controls.
Among the included articles described in Table 1, four
selected esophageal cancer patients based on endoscopy
or histological diagnosis [24-26,31], while the other four
[27-30] selected cases that underwent esophagectomy
without prior radio- and/or chemotherapy. All the con-
trols were recruited in the same period as the cases.
However, the source of the controls for each study was
not similar. In the included studies, five studies [27-31]
selected healthy individuals as controls, while three
[24-26] chose hospital patients as controls.
In addition, among these eligible studies, two included
populations that were selected from ESCC patients
[26,29], four from EAC patients [24,27,28,30], while the
other two did not clarify the histological type [25,31].
Meta-analysis database
Overall, the eligible studies included 1,124 cases and
1,510 controls that were genotyped. The prevalence rates
Table 1 The studies summary of NQO1 C609T polymorphism with esophageal cancer
Ref. Investigator Year Country Race Eligible subjects Characteristic Source of
controls
Method
Cases Controls ESCC EAC Cases Controls
[25] Hamajima
et al.
2002 Japan Asian 102 241 * * The patients were invited to participate
in the present study by doctors in charge.
They were enrolled between March 1999
and December 2000 at Aichi Cancer Center
Hospital.
Controls were sampled from patients at
Aichi Cancer Center Hospital during the
same period as for the cases; participants
in a Helicobacter pylori eradication program







2003 Germany Caucasian 61 252 0 61 Patients who underwent oesophagectomy
for oesophageal adenocarcinoma between
1987 and 2001.
Healthy blood donors of the Heinrich Heine
University Blood Donation Centre between
1995 and 2001. They were from the same







2003 Germany Caucasian 257 252 257 0 All ESCC patients that underwent
esophagectomy without prior radio- and/or
chemotherapy between 1978 and 1998 in
the Department of Surgery of the Heinrich
Heine University, Duesseldorf.
The healthy controls from the German
Caucasian population were unrelated







2003 China Asian 317 306 193 124 All ESCC patients that underwent
esophagectomy without prior radio- and/or
chemotherapy between 2001 and 2002 in
the Fourth Affiliated Hospital, Hebei Medical
University.
The healthy controls from the northern
Chinese population were unrelated blood







2005 Germany Caucasian 140 260 0 140 The patients that underwent
esophagectomy without prior radio- or
chemotherapy between 1991–2003 at the
Technical University of Munich.
Healthy volunteers subjects hospitalized







2006 China Asian 106 106 * * The patients were diagnosed for primary
esophageal cancer by pathology or
endoscopy between 2003–2004, they were
Han Chinese person.
The healthy controls from the same region








2007 UK Caucasian 141 93 0 141 The patients were diagnosed based on
endoscopic and histological evidence.
Control individuals had been recruited
from a dyspepsia endoscopy list, 44 of
these (47%) reported reflux-related







2010 Iran Caucasian 93 50 93 0 The criteria for enrollment patients were an
age of at least 18 years and be resident of
the study area at registration time, with no
concurrent or previous history of other
cancer in any organ.
Controls with no malignancy and/or severe
diseases, were enrolled between the years
2002 and 2008, with the same age and
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Asian descent and 4.1% in the controls of Caucasian
descent. The prevalence rates of CT for controls of
Caucasian and Asian decent were 45.5% and 31.7%, re-
spectively. For histological type, the prevalence rates of
TT were 8.6% and 7.3% in controls of ESCC and EAC
patients, respectively, while CT were 40.9% and 34.0%
in controls of ESCC and EAC patients, respectively.
The genotype distribution and all the P-values for
HWE testing are shown in Tables 2 and 3.
Main results, subgroup analyses
NQO1 C609T polymorphism and ethnic group
The results of the included studies regarding the associ-
ation between the NQO1 C609T polymorphism and
esophageal cancer were conflicting, as seen in Table 1.
Hamajima et al [25], Rahden et al [28], Zhang et al [31]
and Marjani et al [26] showed no significant association
with esophageal cancer. However, the other four studies
showed a significant association with esophageal cancer
[24,27,29,30]. All the included studies were in HWE.
After sensitivity analysis, Hamajima et al [25] and
Martino et al [24] had the highest sensitivity, and were
removed because the controls included no healthy
people, which was determined by reading the full text.
After removing these two articles, the phenotyped sam-
ples contained 974 cases and 1,226 controls.
Using the inverse variance fixed effects model, the
ORs of the pooled NQO1 T allele frequencies were 1.32
(95% CI: 1.08-1.62) for Caucasians and 1.32 (95% CI:
1.08-1.60) for Asians. In total, the summary OR for all
the studies was 1.32 (95% CI: 1.15-1.52). It was shown
that the T allele was related to susceptibility to esopha-
geal cancer.
According to the principle of genetic model selection
by Thakkinstian [17], the recessive model was deter-
mined. The summary result showed a significant rela-
tionship between the NQO1 C609T polymorphism andTable 2 Frequency of NQO1 C609T polymorphism in differen
Ref. Investigator Year Sample
size (%)
Race
[25] Hamajima et al. 2002 343(10.47) Asian
[27] Sarbia et al. 2003 313(9.55) Caucasian
[29] Zhang JH et al. 2003 509(15.54) Caucasian
[29] Zhang JH et al. 2003 499(15.23) Asian
[30] Zhang JH et al. 2003 623(19.02) Asian
[28] Rahden et al. 2005 400(12.21) Caucasian
[31] Zhang WC et al. 2006 212(6.47) Asian
[24] Martino et al. 2007 234(7.14) Caucasian
[26] Marjani et al. 2010 143(4.37) Caucasianesophageal cancer (Figure 1) from the meta-analysis of
the phenotype studies. For the recessive model, the over-
all pooled odds ratio using a fixed effect model was 1.65
(95% CI: 1.23-2.20). The ORs for Caucasians and Asians
were 2.03 (95% CI:1.14-3.61) and 1.53 (95% CI:1.10-
2.14), respectively. Through heterogeneity analysis, we
found no evidence for heterogeneity among the studies
(for the recessive model, I2 = 0.0%, P = 0.48). In addition,
Egger’s test showed that publication bias was not signifi-
cant under the recessive model (P = 0.69).
NQO1 C609T polymorphism and histological type of
esophageal cancer
Six case-control articles reporting an association be-
tween the NQO1 C609T polymorphism and the histo-
logical type of esophageal cancer were included in our
research, but their results were debatable. For EAC,
Martino et al [24] and Zhang et al [30] showed a signifi-
cant association, but Rahden et al [28] showed no sig-
nificant correlation. For ESCC, Sarbia et al [27] and
Zhang et al [29] showed a significant association, but
Marjani et al [26] did not. After removing this study, the
samples of different histological types contained 868
cases and 1,120 controls.
The recessive model was selected according to the
principle of Thakkinstian [17]. The summary result from
the meta-analysis of the phenotype studies indicated a
significant relationship between the NQO1 C609T poly-
morphism and the histological type of esophageal cancer
(Figure 2). For the recessive model, the overall pooled
odds ratio using the fixed effect model was 1.82 (95% CI:
1.32-2.52). The ORs of ESCC and EAC were 2.03 (95%
CI:1.29-3.19) and 1.61 (95% CI:1.01-2.56), respectively.
Through heterogeneity analysis, we found no evidence
for heterogeneity among the studies (for the recessive
model, I2 = 0.0%, P = 0.44). Finally, Egger’s test showed
that publication bias was not significant under the reces-
sive model (P = 0.74).t populations included in a meta-analysis
Cases (%) Controls (%) P value
for HWECC CT TT CC CT TT
36.3 51.0 12.7 35.7 44.4 19.9 0.165
49.2 47.5 3.3 73.4 25.0 1.6 0.602
71.2 21.8 7.0 73.4 25.0 1.6 0.602
26.4 47.7 25.9 34.0 49.6 16.3 0.765
32.3 44.4 23.4 31.5 52.1 16.4 0.390
65.0 30.0 5.0 71.2 25.0 3.8 0.166
26.4 46.2 27.4 40.6 35.8 23.6 0.007
68.1 30.5 1.4 59.1 35.5 5.4 0.986
54.8 37.6 7.5 44.0 48.0 8.0 0.467
Table 3 Frequency of NQO1 C609T polymorphism in ESCC and EAC patients included in a meta-analysis
Ref. Investigator Year Histological
type
Cases (%) Controls (%) P value
for HWECC CT TT CC CT TT
[27] Sarbia et al. 2003 EAC 49.2 47.5 3.3 73.4 25.0 1.6 0.602
[29] Zhang et al. 2003 ESCC 71.2 21.8 7.0 73.4 25.0 1.6 0.602
[29] Zhang et al. 2003 ESCC 26.4 47.7 25.9 34.0 49.6 16.3 0.765
[30] Zhang et al. 2003 EAC 32.3 44.4 23.4 31.5 52.1 16.4 0.390
[28] Rahden et al. 2005 EAC 65.0 30.0 5.0 71.2 25.0 3.8 0.166
[26] Marjani et al. 2010 ESCC 54.8 37.6 7.5 44.0 48.0 8.0 0.467
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the results of the meta-analysis, we performed additional
analysis. We only used the samples from Germany and
China to test the ethnicity effect. The ORs of Germany
and China were 1.68 (95% CI: 1.13-2.51) and 1.96 (95%
CI: 1.36-2.82), respectively. There was no obvious differ-
ence in the results from Caucasian and Asian patients.Figure 1 The forest plot describing the meta- analysis with a fixed-ef
NQO1 C609T polymorphism with esophageal cancer. Each study is dep
the respective 95% confidence intervals. Values of OR > 1, implied an increaDiscussion
NQO1 acts as an imperative part of the cellular antioxi-
dant defense system by detoxifying quinines and can
prevent the formation of reactive oxygen species. NQO1
gene mutations are linked to tardive dyskinesia, which
increases the risk of hematotoxicity after exposure to
benzene, and susceptibility to various forms of cancer.fect recessive model (TT versus CT + CC) for the association of
icted with size inversely proportional to its variance, accompanied by
sed risk for esophageal cancer with the TT genotype.
Figure 2 The forest plot describing the meta- analysis with a fixed-effect recessive model (TT versus CT + CC) for the association of
NQO1 C609T polymorphism with ESCC and EAC. Each study is depicted with size inversely proportional to its variance, accompanied by the
respective 95% confidence intervals. Values of OR > 1, implied an increased risk for esophageal cancer with the TT genotype.
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http://www.biomedcentral.com/1471-2350/14/31Many studies have been carried out to test the hypothesis
that the NQO1 C609T polymorphism might be linked to
the risk of esophageal cancer, but the results are contro-
versial. This meta-analysis, involving a total of 1,217
esophageal cancer patients and 1,560 controls from eight
case-control studies, examined the association of one
polymorphisms of the NQO1 gene with esophageal can-
cer risk. The OR of the pooled NQO1 T allele frequen-
cies for all the studies was 1.32 (95% CI: 1.15-1.52). In
addition, significant evidence was found for a correlation
between the NQO1 C609T variant and esophageal cancer
under the recessive model (OR = 1.647; 95%CI = 1.233-
2.200). Similar to our study, other reports have also
shown an association of NQO1 609C > T polymorphism
with susceptibility to esophageal tumors. Marjani et al
[26] observed that NQO1 expression in esophageal
tumor tissue was related to the NOQ1C609T genotype,
with its expression elevated when the T allele appeared in
the NOQ1C609T genotype.Different enzymes encoded by varying NQO1genotypes
may affect enzyme activities, and the lack of NQO1 activ-
ity encoded by the homozygous TT genotype might re-
sult in reduced detoxification of exogenous carcinogens.
Traver et al [32] confirmed that the NQO1 homozygous
variant (TT) had very little or no quinine reductase activ-
ity; however, compared to the homozygote (CC), the het-
erozygote variant (CT) showed approximately one-third
of the enzymatic activity. Recent studies have identified a
C➙ T mutation in NQO1 [33]. Two to 4% of the global
human population carry both mutant alleles and are de-
ficient in NQO1. Mice lacking NQO1 gene expression
accumulate lower amounts of abdominal fat and show
increased sensitivity to menadione-induced hepatic tox-
icity compared to wild type mice [11,12]. Delwin et al
[13] showed that loss of NQO1 caused mycloid hyper-
plasia of the bone marrow and significant increases in
blood neutrophils, eosinophils and basophils in NQO1-
null mice.
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http://www.biomedcentral.com/1471-2350/14/31A heterogeneity evaluation is always conducted in stat-
istical analysis in meta-analysis. However, we found low
statistical power during heterogeneity testing. Therefore,
several subgroup meta-analyses were performed
according to ethnicity, control source and case classifica-
tion. In the racial subgroups, there was a statistically sig-
nificant asssociation between the NQO1 polymorphism
and esophageal cancer. The ORs for Caucasians and
Asians were 2.03 (95% CI:1.14-3.61) and 1.53 (95%
CI:1.10-2.14), respectively. This showed a possible role
of ethnic divergence. Wang et al [34] also noted that
the overall frequency of the NQO1 609 T allele was
nearly double among Asians than in Europeans in both
patients and controls. There is a wide ethnic variation
in allelic frequencies of NQO1 609C > T according to
the Hapmap database (www.hapmap.ncbi.nlm.nih.gov):
18.6% in Europeans (CEU) and 50% in Asian popula-
tions (HCB).
The results of this meta-analysis should be interpreted
with some caution because there were limitations in our
analysis. First, selection bias was a possible major source
of heterogeneity from uncontrolled confounders and
bias inherent in the study design. For example, there was
not an identical criterion for cases and controls among
all the included articles. Second, different genotype ra-
tios may have a potential impact on the outcomes. The
rate of the TT genotype was very low in Caucasian sub-
jects (fewer than 10% of all Caucasian studies), but
showed a moderate distribution in Asians (more than
15% in all Asian studies). Third, we only considered the
NQO1 C609T polymorphism in esophageal cancer.
However, there may be a possible interaction between
the NQO1 C609T polymorphism and other environ-
mental factors.Conclusions
In summary, the present meta-analysis provides infor-
mation that the NQO1 C609T polymorphism consider-
ably increases susceptibility to or prognosis of
esophageal cancer, especially in ESCC patients. Add-
itional population-based studies in large sample sizes
should be conducted before its clinical application.Competing interests
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